Finerenone Trial Data Shows Potential for Kidney Health

New clinical trial results indicate finerenone provides protective benefits for patients with various kidney disease subtypes.

Updated on Oct. 23, 2026 in Diabetes

A close-up of clear laboratory vials on a shelf, evoking the precision of medical research and clinical kidney disease treatment. — New phase 3 clinical trial results presented at ASN Kidney Week 2026 indicate that finerenone provides protective benefits in slowing kidney function decline. AI Illustration. Upload story photo >

Live Poll

Do you believe new pharmaceutical advances are effectively improving long-term health outcomes for diabetes patients?

Researchers presented phase 3 trial findings at the ASN Kidney Week 2026 conference detailing the efficacy of finerenone for chronic kidney disease patients. The study results offer new insights into treating both diabetic and non-diabetic kidney conditions.

Why it matters

Medical experts aim to determine if short-term markers like reduced albuminuria translate into long-term kidney protection. These findings help clarify the role of finerenone as a supportive treatment alongside standard inhibitors.

The FINE-ONE trial enrolled 242 adults, while the FIND-CKD trial included 1,584 participants. Among non-diabetic patients, IgA nephropathy and focal segmental glomerulosclerosis accounted for 46.1% and 23.8% of cases respectively.

The players

American Society of Nephrology

This professional organization hosts the annual Kidney Week conference to showcase advancements in kidney research and clinical nephrology.

Food and Drug Administration

This federal agency is responsible for regulating medical treatments and recently authorized the use of finerenone for specific diabetic patients.

The details

The FIND-CKD trial showed that finerenone slowed the annual decline of estimated glomerular filtration rate by 0.7 mL/min/1.73 m2. In patients with focal segmental glomerulosclerosis, the medication reduced the eGFR decline rate to 4.7 mL/min/1.73 m2 per year.

September 2026: The FDA approved finerenone for patients with type 1 diabetes and chronic kidney disease.
October 21-25, 2026: Researchers presented trial data at the ASN Kidney Week 2026 conference.

Health Landscape

The presentation of these phase 3 trials follows a pattern established by the ASN Kidney Week conference in elevating new clinical data for renal therapeutics. This research bridges existing treatment gaps by exploring how newer medications can complement long-standing RAS and SGLT2 inhibitor protocols.

Patients with type 1 diabetes and chronic kidney disease may discuss these treatment options with their nephrologist following the recent FDA approval. The data highlights how finerenone is designed to act as a supportive medication to slow kidney function decline alongside existing therapies.

The takeaway

These findings suggest that finerenone could serve as a valuable tool for managing kidney health across a broader range of patients. Patients should consult with their healthcare providers to determine how emerging treatment protocols may fit into their current kidney management plan.